GoodRx (GDRX) FDA Approvals $3.35 -0.01 (-0.30%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$3.33 -0.02 (-0.60%) As of 09/25/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest GoodRx's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by GoodRx (GDRX). Over the past two years, GoodRx has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Zepbound. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Zepbound FDA Regulatory Events Zepbound is a drug developed by GoodRx for the following indication: for chronic weight management in adults with obesity. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Provided Update - March 6,2026Provided Update Drug: ZepboundAnnounced Date: March 6, 2026Indication: for chronic weight management in adults with obesityAnnouncementGoodRx announced employer-sponsored access to Zepbound® (tirzepatide) KwikPen® (for single-patient-use) through GoodRx Employer Direct.AI SummaryGoodRx announced a collaboration with Eli Lilly to offer employer-sponsored access to Zepbound® (tirzepatide) KwikPen® (single-patient-use) through GoodRx Employer Direct. The program lets self-insured employers subsidize Lilly’s discounted $449 medication price so employees face lower out-of-pocket costs for Zepbound KwikPen. Employer contributions are applied directly to the medication cost, and GoodRx combines the manufacturer’s discounted pricing with employer funding in real time at checkout. The service also offers optional telemedicine to help with prescribing and fulfillment, aiming to simplify how employees obtain and pay for the medicine. GoodRx describes the model as a scalable, transparent way for employers to manage rising demand for GLP-1 obesity treatments while helping employees afford therapy. The partnership is positioned to expand access to Zepbound while giving employers a predictable way to support medication costs.Read Announcement GoodRx FDA Events - Frequently Asked Questions Has GoodRx received FDA approval? As of now, GoodRx (GDRX) has not received any FDA approvals for its therapy in the last two years. What drugs has GoodRx submitted to the FDA? In the past two years, GoodRx (GDRX) has reported FDA regulatory activity for Zepbound. What is the most recent FDA event for GoodRx? The most recent FDA-related event for GoodRx occurred on March 6, 2026, involving Zepbound. The update was categorized as "Provided Update," with the company reporting: "GoodRx announced employer-sponsored access to Zepbound® (tirzepatide) KwikPen® (for single-patient-use) through GoodRx Employer Direct." What conditions do GoodRx's current drugs treat? Currently, GoodRx has one therapy (Zepbound) targeting the following condition: for chronic weight management in adults with obesity. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events C4 Therapeutics FDA EventsLegend Biotech FDA EventsOcugen FDA EventsBristol Myers Squibb FDA EventsJohnson & Johnson FDA EventsMerck & Co., Inc. FDA EventsACADIA Pharmaceuticals FDA EventsAnnexon FDA EventsBioLineRx FDA EventsEnsysce Biosciences FDA EventsLakewood-Amedex Biotherapeutics FDA EventsEthos Technologies Inc. Class A Common Stock FDA EventsMesoblast FDA EventsMediciNova FDA EventsSatellos Bioscience FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Heartflow FDA Events Aclarion FDA Events Adaptive Biotechnologies FDA Events Veradermics FDA Events Relay Therapeutics FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:GDRX last updated on 3/6/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GoodRx Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GoodRx With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Provided Update - March 6,2026Provided Update Drug: ZepboundAnnounced Date: March 6, 2026Indication: for chronic weight management in adults with obesityAnnouncementGoodRx announced employer-sponsored access to Zepbound® (tirzepatide) KwikPen® (for single-patient-use) through GoodRx Employer Direct.AI SummaryGoodRx announced a collaboration with Eli Lilly to offer employer-sponsored access to Zepbound® (tirzepatide) KwikPen® (single-patient-use) through GoodRx Employer Direct. The program lets self-insured employers subsidize Lilly’s discounted $449 medication price so employees face lower out-of-pocket costs for Zepbound KwikPen. Employer contributions are applied directly to the medication cost, and GoodRx combines the manufacturer’s discounted pricing with employer funding in real time at checkout. The service also offers optional telemedicine to help with prescribing and fulfillment, aiming to simplify how employees obtain and pay for the medicine. GoodRx describes the model as a scalable, transparent way for employers to manage rising demand for GLP-1 obesity treatments while helping employees afford therapy. The partnership is positioned to expand access to Zepbound while giving employers a predictable way to support medication costs.Read Announcement
